Acmg Cnv Calculator

Clinical Genetics Tool

Estimate an evidence-based copy number variant classification score using a practical ACMG and ClinGen style point framework. This tool is designed for education, triage, and workflow support. It does not replace laboratory-grade interpretation, phenotype review, or formal board-certified clinical judgment.

Expert guide to the ACMG CNV calculator

The ACMG CNV calculator is a structured aid for interpreting copy number variants, commonly abbreviated CNVs, in a way that aligns with the evidence-weighting philosophy used by the American College of Medical Genetics and Genomics and the ClinGen community. In daily genomic practice, CNV interpretation is rarely a single-variable decision. A deletion or duplication can involve dosage-sensitive genes, sit inside a well-established benign region, arise de novo, segregate in a family, or appear among healthy controls. The purpose of a calculator is not to replace expert interpretation, but to help clinicians, laboratory directors, genetic counselors, and researchers organize evidence into a transparent scoring framework.

CNVs include deletions and duplications ranging from very small intragenic events to multi-megabase chromosomal gains or losses. Their clinical significance depends on several biological and contextual factors: gene content, known dosage sensitivity, overlap with benign copy number regions, case-level inheritance data, and phenotype concordance. Because these factors can point in different directions, a point-based interpretation model improves consistency. That is why a high-quality ACMG CNV calculator can be valuable in variant review meetings, report drafting, and educational settings.

Important: The calculator on this page provides an educational estimate of CNV pathogenicity classification. A final classification should always include locus-specific literature review, assay performance limits, breakpoint quality, zygosity, transcript impact, and a complete clinical correlation workflow.

Why CNV classification is more complex than size alone

A common misconception is that larger CNVs are automatically more pathogenic. In reality, size is only one clue. A 5 Mb duplication in a gene-poor, tolerance-heavy region may be less clinically significant than a 60 kb deletion that disrupts a critical haploinsufficient gene. The ACMG and ClinGen framework therefore emphasizes content and evidence rather than relying solely on length. Still, size often correlates with gene count and the probability of disrupting multiple dosage-sensitive loci, so many interpretation workflows use size as a supportive heuristic.

Another complicating factor is event type. Deletions and duplications are not equivalent. Some genes are strongly haploinsufficient, meaning one lost copy can cause disease. Others show triplosensitivity, meaning an extra copy can be clinically relevant. For many loci, one mechanism is well established while the other is weak or absent. Therefore, a serious ACMG CNV calculator should always start by separating deletions from duplications and then layering in dosage-specific evidence.

Core evidence categories in an ACMG CNV calculator

• CNV type: Deletions often have stronger immediate concern for gene loss, but duplications can be highly relevant in triplosensitive regions.
• Size and gene count: Larger CNVs can affect more genes, increasing the chance of dosage impact, though not always.
• Known disease genes: Overlap with genes that have established disease relationships materially changes the evidence profile.
• Dosage sensitivity data: ClinGen dosage curation is particularly useful for evaluating whether loss or gain is biologically plausible as a disease mechanism.
• Overlap with benign CNV regions: Strong overlap with recurrent benign regions can significantly lower the likelihood of pathogenicity.
• Inheritance: A confirmed de novo event in a well-matched phenotype is much stronger evidence than an inherited event from an unaffected parent.
• Phenotype match: A genomic event becomes more compelling when the patient presentation closely aligns with the known syndrome spectrum.
• Population frequency: Common CNVs in unaffected populations are usually benign or likely benign, assuming no hidden ascertainment issue.

How the point-based CNV framework maps to classification

Many labs use score thresholds that roughly align with ACMG and ClinGen practice. In a practical scoring system, evidence accumulates toward pathogenicity or benignity. Strongly positive evidence can place a CNV into a pathogenic or likely pathogenic range, while strongly negative evidence can support likely benign or benign classification. Variants that lack enough positive or negative support remain variants of uncertain significance, often abbreviated VUS.

Classification	Typical score range	Interpretive meaning
Pathogenic	≥ 0.99	Strong evidence supports a disease-causing CNV.
Likely pathogenic	0.90 to 0.98	Evidence leans strongly toward clinical relevance, but may not be fully definitive.
VUS	-0.89 to 0.89	Current evidence is mixed, limited, or insufficient for a directional conclusion.
Likely benign	-0.98 to -0.90	Evidence argues against clinical significance, though not absolutely.
Benign	≤ -0.99	Strong evidence indicates the CNV is not disease-causing in the evaluated context.

These cutoffs are useful because they create reproducibility. If one analyst can explain how a CNV reached a score of 1.10 while another can independently reproduce a similar total, the team has a much stronger basis for report wording and quality control. However, it is equally important to remember that not every evidence item is independent. Some findings, such as size, gene count, and known disease gene overlap, can be correlated. Skilled interpretation means avoiding the temptation to over-count related data.

What real-world data tell us about genomic variation

Population-scale sequencing and structural variant studies have shown that CNVs are common in the human genome. Each person carries many structural variants, and only a small fraction are clinically significant. This is one reason why benign overlap and control frequency matter so much. In constitutional genomics, the challenge is not merely finding a CNV. The challenge is determining whether that CNV explains the observed phenotype.

Measure	Representative statistic	Why it matters for CNV interpretation
Structural variants per human genome	Thousands of structural variant calls can be identified depending on platform and pipeline	Most detected variants are not pathogenic, so filtering and evidence weighting are essential.
Clinically relevant CNVs in rare disease workflows	Diagnostic yield commonly falls in the single-digit to low double-digit percent range, depending on cohort and technology	Only a minority of CNVs explain disease, reinforcing the need for standardized scoring.
Common benign CNVs	Many recurrent CNVs are present in healthy populations	Control datasets prevent overcalling routine population variation as pathogenic.

Those broad statistics help place the ACMG CNV calculator in context. The tool exists because the genomic background is noisy. Interpretation requires disciplined integration of rare disease evidence, dosage biology, and population reference data. A calculator supports that integration, particularly when many cases must be reviewed efficiently.

How to use this ACMG CNV calculator effectively

1. Choose the CNV type: Start by specifying deletion or duplication. This matters because gain and loss mechanisms differ by gene and locus.
2. Enter size and gene count: These fields approximate the structural burden of the event. They should come from a reliable calling and annotation pipeline.
3. Add disease gene information: If the CNV hits genes with established disease association, enter the number thoughtfully rather than inflating the count with weak candidates.
4. Set dosage sensitivity evidence: Favor curated dosage data whenever possible. ClinGen dosage curation is especially helpful.
5. Account for benign overlap: If the CNV lies within a known benign region, apply negative weight.
6. Evaluate inheritance: Confirmed de novo events can be highly informative, while inherited variants from unaffected parents often reduce pathogenic confidence.
7. Consider phenotype match: A highly specific clinical match can elevate confidence substantially.
8. Review population context: Common findings in controls usually push interpretation toward benignity.

After the score is calculated, treat the output as a structured summary, not the end of the process. For example, a likely pathogenic score should still prompt review of breakpoint confidence, mosaicism, transcript-specific effects, and literature consistency. Conversely, a VUS score does not mean the CNV is unimportant. It may simply reflect incomplete evidence today. Many uncertain CNVs are later reclassified when segregation studies, additional patient reports, or improved dosage curation become available.

Deletion versus duplication, practical interpretation differences

In general, deletions may more readily create a loss-of-function state by removing coding exons or whole genes. For known haploinsufficient genes, even small deletions can be compelling. Duplications are more nuanced. An extra copy does not always disrupt gene regulation in a predictable way. Tandem, inserted, and complex duplications may have distinct functional consequences. Triplosensitive genes and recurrent duplication syndromes are therefore especially important references when judging gain events.

This distinction is why many workflows assign slightly different baseline heuristics to deletion and duplication categories. In the calculator above, large deletions and deletion-heavy gene content may contribute more weight than equivalent duplications unless other triplosensitivity evidence is present. That is not a universal rule, but it reflects common clinical experience.

Where to verify evidence with authoritative sources

For rigorous interpretation, always verify your evidence using authoritative sources. Good starting points include the National Center for Biotechnology Information, the National Human Genome Research Institute, and university-hosted genetics resources. You can review genomic concepts and structural variant context at the National Human Genome Research Institute. Broader genomic databases and literature indexing are available through the National Center for Biotechnology Information. For educational review of chromosome microarray and genomic medicine concepts, many clinicians also use resources from academic centers such as the MedlinePlus Genetics program of the U.S. National Library of Medicine.

Common pitfalls when using an ACMG CNV calculator

• Over-counting correlated evidence: A large CNV with many genes and several disease genes should not be double-counted in a way that artificially inflates certainty.
• Ignoring assay limitations: Array, exome, and genome sequencing pipelines can differ in breakpoint precision and sensitivity for complex rearrangements.
• Using phenotype too loosely: Nonspecific findings such as developmental delay alone should not be treated as a highly specific match without additional syndrome features.
• Underweighting benign overlap: Failure to consider recurrent benign CNVs is a common source of overcalling.
• Confusing rarity with pathogenicity: Rare does not automatically mean disease-causing. Many rare CNVs are simply uncommon benign variation.

Best practices for clinical reporting

When documenting a CNV classification, include the genomic coordinates, reference build, event type, estimated size, affected genes, inheritance status if known, evidence supporting dosage interpretation, and a clear rationale for the final classification. If a calculator score informed the review, state that the score reflects an evidence-weighted framework and list the main factors that drove the result. Transparency improves reproducibility and helps downstream clinicians understand why a CNV was categorized in a particular way.

It is also wise to add a reanalysis plan for uncertain findings. CNV interpretation evolves. New syndrome definitions, better dosage sensitivity curation, and additional control data may significantly change confidence. An ACMG CNV calculator is therefore best viewed as part of a living interpretation ecosystem rather than a static one-time verdict.

Final takeaways

The best ACMG CNV calculator is one that balances structure with caution. It should provide enough granularity to organize deletion and duplication evidence, but remain transparent about its assumptions. Used correctly, a calculator can improve consistency, speed up variant review, and support communication between laboratory and clinical teams. Used carelessly, it can create false precision. The right approach is to treat the score as a disciplined summary of the evidence you currently have, then complete the interpretation with expert genomic, phenotypic, and family-level analysis.

If you are building a case conference workflow, training new analysts, or screening CNVs before deep manual review, a well-designed ACMG CNV calculator can be a powerful first-pass tool. Just remember that clinical genomics remains a high-context discipline. Evidence scoring is invaluable, but expert interpretation is still the final safeguard for quality and patient care.